<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Deep brain stimulation</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Neuropace shows 77% reduction in seizures</title>
      <description>
        <![CDATA[People with drug-resistant epilepsy have had few other options, but Neuropace Inc. appears on target to provide an alternative. The Nautilus trial of its responsive neurostimulation system for individuals with drug-resistant idiopathic generalized epilepsy showed a 77% reduction in generalized tonic-clonic seizures sustained over 18 months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726722</guid>
      <pubDate>Mon, 08 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726722-neuropace-shows-77-reduction-in-seizures</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/06-30-Neuropace-RNS-System.webp?t=1765231786" type="image/png" medium="image" fileSize="531289">
        <media:title type="plain">Illustration of RNS system placement in brain</media:title>
        <media:description type="plain">The implanted RNS system by Neuropace Credit: Neuropace Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Precision Neuro’s minimally invasive BCI effective in early studies</title>
      <description>
        <![CDATA[The brain-computer interface (BCI) system being developed by Precision Neuroscience Corp. is capable of capturing high-resolution brain signals and stimulating areas without damaging the cortical surface, according to a study published in <em>Nature Biomedical Engineering</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724793</guid>
      <pubDate>Mon, 06 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724793-precision-neuros-minimally-invasive-bci-effective-in-early-studies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Layer-7-Cortical-Interface-19dec24.webp?t=1734702556" type="image/jpeg" medium="image" fileSize="179251">
        <media:title type="plain">Layer 7 Cortical Interface</media:title>
        <media:description type="plain">Layer 7 Cortical Interface. Credit: Precision Neuroscience</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic’s adaptive DBS safe, effective in people with Parkinson’s</title>
      <description>
        <![CDATA[Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in the <em>Journal of the American Medical Association (JAMA) Neurology</em> found that the majority of participants who received aDBS with the Percept neurostimulator achieved good ‘on-time’ without troublesome dyskinesia compared to standard continuous DBS therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724490</guid>
      <pubDate>Thu, 02 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724490-medtronics-adaptive-dbs-safe-effective-in-people-with-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Medtronics-Brainsense-adaptive-DBS-2oct25.webp?t=1759438075" type="image/jpeg" medium="image" fileSize="220345">
        <media:title type="plain">Medtronic Brainsense adaptive DBS</media:title>
        <media:description type="plain">Medtronic Brainsense adaptive deep brain stimulation system. Credit: Medtronic plc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop visual prosthetic to restore sight</title>
      <description>
        <![CDATA[Researchers from the Albert Einstein College of Medicine filed for protection of the development of a lateral geniculate nucleus (LGN) visual prosthetic device with implantable electrode arrays that stimulate the LGN and restore vision.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718006</guid>
      <pubDate>Fri, 21 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718006-researchers-develop-visual-prosthetic-to-restore-sight</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/Implantable-electrode-assemblies-3-20.webp?t=1742593582" type="image/jpeg" medium="image" fileSize="136221">
        <media:title type="plain">Implantable electrode assemblies</media:title>
        <media:description type="plain">WO2025049400-A1, “Implantable electrode assemblies, including implantable electrode assemblies for the brain, and associated systems, devices, and methods.”Assignee: Albert Einstein College of Medicine; Raven Neuro Inc.

Inventors: Eskandar, Emad; Killian, Nathaniel; Shank, AaronIPC codes: A61B 18/14; A61N 1/05; A61N 1/36

Publication date: March 6, 2025Earliest priority details: US2023578718, Aug. 25, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Vivani looking to get slim with Cortigent neurostimulation spin</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported plans to spin off Cortigent, the division that develops brain implants. Vivani said it plans to create two focused companies dedicated to driving current and future value in their respective therapeutic areas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718309</guid>
      <pubDate>Thu, 13 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718309-vivani-looking-to-get-slim-with-cortigent-neurostimulation-spin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-merger-acquisition-cancel-terminate.webp?t=1588276898" type="image/png" medium="image" fileSize="211268">
        <media:title type="plain">Hands holding torn contract</media:title>
      </media:content>
    </item>
    <item>
      <title>Vivani looking to get slim with Cortigent neurostimulation spin</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported plans to spin off Cortigent, the division that develops brain implants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717893</guid>
      <pubDate>Wed, 12 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717893-vivani-looking-to-get-slim-with-cortigent-neurostimulation-spin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-merger-acquisition-cancel-terminate.webp?t=1588276898" type="image/png" medium="image" fileSize="211268">
        <media:title type="plain">Hands holding torn contract</media:title>
      </media:content>
    </item>
    <item>
      <title> ​Medtronic‘s Brainsense lands CE mark for Parkinson’s </title>
      <description>
        <![CDATA[Medtronic plc secured CE mark approval under the EU Medical Device Regulation for its Brainsense adaptive deep brain stimulation system. The technology represents a major advancement in the treatment of Parkinson’s disease as it provides real-time, self-adjusting brain stimulation based on the patient’s brain activity, offering a more personalized therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715971</guid>
      <pubDate>Mon, 13 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715971-medtronics-brainsense-lands-ce-mark-for-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Medtronic-adaptive-DBS-System-13jan25.webp?t=1736806915" type="image/jpeg" medium="image" fileSize="138347">
        <media:title type="plain">Medtronic adaptive DBS System</media:title>
        <media:description type="plain">Medtronic adaptive DBS System. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Non-invasive procedure seen as effective, safe for severe OCD</title>
      <description>
        <![CDATA[New research confirmed long-term efficacy and safety of a novel minimally invasive procedure with Insightec Inc.’s Exablate transcanial magnetic resonance-guided focused ultrasound system to alleviate symptoms of severe obsessive-compulsive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714811</guid>
      <pubDate>Fri, 06 Dec 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714811-non-invasive-procedure-seen-as-effective-safe-for-severe-ocd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Insightec-Exablate-Prime--live-scan-6dec24.webp?t=1733519906" type="image/jpeg" medium="image" fileSize="354859">
        <media:title type="plain">Insightec Exablate Prime</media:title>
        <media:description type="plain">Insightec’s Exablate Prime. Credit: Insightec</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA approves Medtronic Asleep DBS surgery, expanded MRI labeling</title>
      <description>
        <![CDATA[The U.S. FDA recently granted Medtronic plc approval for its deep brain stimulation (DBS) system to be used to treat Parkinson’s disease or essential tremor while a patient is asleep, under general anesthesia. The approval gives patients another option for DBS therapy which can transform their quality of life, Amaza Reitmeier, vice president and general manager for Medtronic brain modulation, told BioWorld in an interview.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711385</guid>
      <pubDate>Thu, 22 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711385-fda-approves-medtronic-asleep-dbs-surgery-expanded-mri-labeling</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Medtronic-Percept-RC-11jan24.webp?t=1724359616" type="image/jpeg" medium="image" fileSize="85872">
        <media:title type="plain">Medtronic Percept RC</media:title>
        <media:description type="plain">Medronic Percept RC. Credit: Medtronic</media:description>
      </media:content>
    </item>
    <item>
      <title>Parkinson’s DBS treatment vastly underutilized in the UK</title>
      <description>
        <![CDATA[As new treatment options are being continually investigated and trialed against Parkinson’s disease, the possibilities offered by deep brain stimulation (DBS) risk being overlooked. Though not a cure, the therapy could vastly improve the quality of life for patients with the disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709482</guid>
      <pubDate>Wed, 19 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709482-parkinsons-dbs-treatment-vastly-underutilized-in-the-uk</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Boston-Scientific-Vercise-Genus-system-19june24.webp?t=1718831678" type="image/jpeg" medium="image" fileSize="129269">
        <media:title type="plain">Boston-Scientific-Vercise-Genus-system-19june24.jpg</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic wins FDA approval for pain-sensing spinal cord stimulator</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Medtronic plc said it secured U.S. FDA approval for its first closed-loop spinal cord stimulator (SCS), designed to take in signals from the body and adjust its therapy automatically.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707922</guid>
      <pubDate>Wed, 01 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707922-medtronic-wins-fda-approval-for-pain-sensing-spinal-cord-stimulator</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Medtronic-Inceptiv-neurostimulator-8-25.webp?t=1692993837" type="image/jpeg" medium="image" fileSize="153116">
        <media:title type="plain">Medtronic's Inceptiv neurostimulator</media:title>
        <media:description type="plain">Medtronic's Inceptiv spinal cord stimulator</media:description>
      </media:content>
    </item>
    <item>
      <title>Deep brain stimulation of central thalamus restores consciousness in primate models</title>
      <description>
        <![CDATA[A research team led by neuroscientists and neurosurgeons from Paris-Saclay University have recently managed to demonstrate that electrical stimulation of the thalamus can restore consciousness when this has been impaired.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518166</guid>
      <pubDate>Fri, 22 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518166-deep-brain-stimulation-of-central-thalamus-restores-consciousness-in-primate-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Cross-section-of-brain.webp?t=1636061320" type="image/png" medium="image" fileSize="444252">
        <media:title type="plain">Cross section of brain</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA approval stimulates Boston Scientific’s Neural Navigator</title>
      <description>
        <![CDATA[Boston Scientific Corp.’s image-guided programming software, Vercise Neural Navigator with Stimview XT, got the green light from the FDA for use with the company’s deep brain stimulation (DBS) portfolio in patients with essential tremor or Parkinson’s disease. The software, developed in a collaboration with Brainlab AG, provides more sophisticated image-guided programming tools for personalization of the stimulation therapy, halving the time needed for adjustments and increasing precision.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517866</guid>
      <pubDate>Tue, 12 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517866-fda-approval-stimulates-boston-scientifics-neural-navigator</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/04-12-Boston-Scientific-DBS-Stimview.webp?t=1649801270" type="image/png" medium="image" fileSize="372189">
        <media:title type="plain">Vercise Neural Navigator with Stimview XT software on tablet</media:title>
        <media:description type="plain">Boston Scientific Corp.’s Stimview XT.</media:description>
      </media:content>
    </item>
    <item>
      <title>Method for identifying neural circuits that cause depression may lead to tailored therapies</title>
      <description>
        <![CDATA[LONDON – Fixed and constant deep brain stimulation has been successful in treating Parkinson’s disease and epilepsy, but heterogeneity in individual response means that despite promise, clinical studies in serious depression have to date delivered inconsistent results. U.S. researchers have now developed a method for identifying the neural circuits underlying symptoms of depression in individual patients and applied this to deliver tailored therapy, using a commercially available device to stimulate the brain when these circuits are activated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512026</guid>
      <pubDate>Mon, 04 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512026-method-for-identifying-neural-circuits-that-cause-depression-may-lead-to-tailored-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/neurology-depression.webp?t=1745265126" type="image/jpeg" medium="image" fileSize="410355">
        <media:title type="plain">Silhouette made of crumpled paper illustrating depression</media:title>
      </media:content>
    </item>
    <item>
      <title>Aleva launches postmarket study on its directional DBS system for neurology conditions</title>
      <description>
        <![CDATA[PARIS &ndash; Aleva Neurotherapeutics SA reported the first successful implantation of its Directstim directional deep brain stimulation (DBS) system into a patient suffering from Parkinson&rsquo;s disease. The procedure involving this new generation of active brain device was performed by neurosurgeon Stephan Sobottka, from the Clinic for Neurosurgery at the University Hospital Carl Gustav Carus in Dresden, Germany. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/509433</guid>
      <pubDate>Fri, 16 Jul 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509433-aleva-launches-postmarket-study-on-its-directional-dbs-system-for-neurology-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/07-16-Aleva-Neurotherapeutics-Directstim.webp?t=1626465540" type="image/png" medium="image" fileSize="429692">
        <media:title type="plain">Directstim device image</media:title>
        <media:description type="plain">Directstim directional deep brain stimulation system. Credit: Aleva Neurotherapeutics SA</media:description>
      </media:content>
    </item>
    <item>
      <title>Inbrain raises $17M to bring nanoscale graphene implants to clinical development</title>
      <description>
        <![CDATA[LONDON &ndash; Inbrain Neuroelectronics Ltd. has raised &euro;14.35 million (US$16.9 million) in a series A round to take nanoscale graphene implants it says have the potential to interface one-on-one with neurons, into clinical development later this year. The technology promises significant improvements on current implants used for deep brain stimulation to treat conditions including Parkinson&rsquo;s disease, epilepsy, obsessive compulsive disorder and neuropathic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505368</guid>
      <pubDate>Tue, 30 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505368-inbrain-raises-17m-to-bring-nanoscale-graphene-implants-to-clinical-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Bag-of-euros.webp?t=1588782344" type="image/png" medium="image" fileSize="277908">
        <media:title type="plain">Bag of euros </media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic secures CE mark for directional lead system for deep brain stimulation</title>
      <description>
        <![CDATA[Medtronic plc obtained the CE mark for its Sensight directional lead system for deep brain stimulation (DBS) for movement disorders and epilepsy, which is designed to be used with the company&rsquo;s Percept PC DBS device. Percept received U.S. FDA clearance in June 2020 and CE mark in January 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505022</guid>
      <pubDate>Mon, 22 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505022-medtronic-secures-ce-mark-for-directional-lead-system-for-deep-brain-stimulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-22-Medtonic-Sensight-Percept.webp?t=1616450533" type="image/png" medium="image" fileSize="838706">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Percept PC neurostimulator with Sensight directional lead system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott launches Neurosphere Virtual Clinic for remote neuromodulation</title>
      <description>
        <![CDATA[COVID-19 continues to dramatically reconfigure medicine as an ever-broadening array of digital therapies rolls out and telemedicine tackles increasingly complex applications. Abbott Laboratories&rsquo; newly launched Neurosphere Virtual Clinic exploits both trends to make management of chronic pain and movement disorders easier for patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/504919</guid>
      <pubDate>Thu, 18 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/504919-abbott-launches-neurosphere-virtual-clinic-for-remote-neuromodulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-18-Abbott-Neurosphere.webp?t=1616103703" type="image/png" medium="image" fileSize="301832">
        <media:title type="plain">Neurosphere Virtual Clinic on a tablet</media:title>
        <media:description type="plain">The Neurosphere Virtual Clinic connects patients with neuromodulation devices and physicians. Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to Boston Scientific’s next-gen Vercise Genus DBS</title>
      <description>
        <![CDATA[Boston Scientific Corp. has received a thumbs up from the U.S. FDA for its fourth-generation Vercise Genus deep brain stimulation (DBS) system. The neuromodulation device, which comes in both rechargeable and nonrechargeable versions, is intended to treat the symptoms of Parkinson&rsquo;s disease. Vercise Genus is indicated for use in the bilateral stimulation of subthalamic nucleus as an adjunctive therapy in alleviating some of the symptoms of moderate to advanced lepodova-responsive Parkinson&rsquo;s disease that are not adequately controlled by medication. It also has indications for bilateral stimulation of the globus pallidus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502729</guid>
      <pubDate>Fri, 22 Jan 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502729-fda-gives-nod-to-boston-scientifics-next-gen-vercise-genus-dbs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-illustration.webp?t=1591647441" type="image/png" medium="image" fileSize="423792">
        <media:title type="plain">Brain illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic kicks off ADAPT-PD study in Parkinson’s patients</title>
      <description>
        <![CDATA[Medtronic plc reported that the first patient has been enrolled in the Adaptive DBS Algorithm for Personalized Therapy in Parkinson&#39;s Disease (ADAPT-PD) study its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson&#39;s disease (PD). This type of stimulation is an investigational feature of the Percept PC device that could be enabled if approved.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502428</guid>
      <pubDate>Thu, 14 Jan 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502428-medtronic-kicks-off-adapt-pd-study-in-parkinsons-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-24-Medtronic-Percept.webp?t=1593122005" type="image/png" medium="image" fileSize="572182">
        <media:title type="plain">Percept PC device with software on phone and tablet</media:title>
        <media:description type="plain">Percept PC. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives green light to Medtronic’s DBS system with brain signal tracking</title>
      <description>
        <![CDATA[Medtronic plc has won the U.S. FDA&rsquo;s nod for the first deep brain stimulation (DBS) system that integrates Brainsense, the company&rsquo;s technology to sense and record brain signals for more personalized treatment. The next-generation Percept PC DBS with Brainsense is approved to treat symptoms associated with Parkinson&rsquo;s disease, essential tremor, dystonia, epilepsy and obsessive-compulsive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436061</guid>
      <pubDate>Thu, 25 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436061-fda-gives-green-light-to-medtronics-dbs-system-with-brain-signal-tracking</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-24-Medtronic-Percept.webp?t=1593122005" type="image/png" medium="image" fileSize="572182">
        <media:title type="plain">Percept PC device with software on phone and tablet</media:title>
        <media:description type="plain">Percept PC. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott gets FDA nod for Infinity DBS in Parkinson’s disease, unveils positive data on Proclaim XR</title>
      <description>
        <![CDATA[Abbott Laboratories had a winning week, scoring U.S. FDA approval of its Infinity directional deep brain stimulation (DBS) system in treating symptoms of Parkinson&rsquo;s disease not adequately managed by medication. The company also reported new data underscoring the benefits of its Proclaim XR neuromodulation system in people living with chronic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432625</guid>
      <pubDate>Fri, 24 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432625-abbott-gets-fda-nod-for-infinity-dbs-in-parkinsons-disease-unveils-positive-data-on-proclaim-xr</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-24-Abbott-Infinity-DBS-hero.webp?t=1579902035" type="image/png" medium="image" fileSize="296960">
        <media:title type="plain">1-24-Abbott-Infinity-DBS-hero.png</media:title>
        <media:description type="plain">Infinity directional deep brain stimulation system.
Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic spotlights pipeline, as Ishrak cedes stage a bit to incoming CEO Martha</title>
      <description>
        <![CDATA[SAN FRANCISCO &ndash; This was the final presentation for Omar Ishrak at the J.P. Morgan (JPM) Healthcare Conference. He has held the CEO position at Medtronic plc since June 2011. During that period, the Dublin-based company managed to roughly quadruple its valuation to $160 billion from $40 billion &ndash; making Ishrak&rsquo;s tenure clearly a successful one.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432370</guid>
      <pubDate>Mon, 13 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432370-medtronic-spotlights-pipeline-as-ishrak-cedes-stage-a-bit-to-incoming-ceo-martha</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/business-performance-pipeline.webp?t=1588793771" type="image/png" medium="image" fileSize="544180">
        <media:title type="plain">Business pipeline illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic gets CE mark for DBS system that tracks brain signals, as it undergoes FDA review</title>
      <description>
        <![CDATA[Dublin-based Medtronic plc received a CE mark for its Percept PC neurostimulator to treat neurologic disorders such as Parkinson&rsquo;s disease. It is the first deep brain stimulation system launched in the EU that integrates the company&rsquo;s technology to sense and record brain signals, known as Brainsense. It&rsquo;s intended to enable more personalized treatment driven by that data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432296</guid>
      <pubDate>Thu, 09 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432296-medtronic-gets-ce-mark-for-dbs-system-that-tracks-brain-signals-as-it-undergoes-fda-review</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-9-medtronic-percept-dbs.webp?t=1578611517" type="image/png" medium="image" fileSize="749694">
        <media:title type="plain">1-9-medtronic-percept-dbs.png</media:title>
        <media:description type="plain">Percept PC neurostimulator with Brainsense technology.
Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>First patient treated in study for mild Alzheimer's using DBS</title>
      <description>
        <![CDATA[<a href="https://www.cortellis.com/intelligence/qsearch/%22Functional%20Neuromodulation%22" target="_blank">Functional Neuromodulation Ltd</a>. is looking to help those suffering from mild Alzheimer's disease. To that end, it recently disclosed that it has kicked off the global ADvance II Study (NCT03622905), a pivotal clinical trial to assess deep brain stimulation (DBS) in these patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430138</guid>
      <pubDate>Mon, 23 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430138-first-patient-treated-in-study-for-mild-alzheimers-using-dbs</link>
    </item>
  </channel>
</rss>
